A 52-year old male patient with lung and liver metastasis (1 st image) of malignant melanoma was advised to start nivolumab therapy (3mg/kg every 3 weeks). After approximately 34 weeks of nivolumab administration, a sharp increase in the liver enzymes (AST/ALT) (1225 /824 U/L) was noticed. However, the patient did not experience any symptoms. CT scans indicated the exacerbation of liver metastasis.
The lesion was localized, nondiffuse, but slightly larger (2 nd image, yellow arrows) than what it was before the therapy was initiated. What could be the most likely reason for the sudden onset of hepatitis? *This case is from Docplexus editorial team for educative purpose only. Source: Case Reports in Oncology Stay connected, the answer will be posted in next 48h!
